Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Firazyr self administration will be key to Shire growth as HAE competition heats up

This article was originally published in Scrip

Executive Summary

While Shire's FAST-3 Phase III trial in which its bradykin B2 receptor antagonist, Firazyr (icatibant) significantly outperformed placebo in the treatment of hereditary angioedema (HAE) should tick an outstanding box with the US FDA and open up the US market to the drug, the success of a separate European trial on the self-administration of Firazyr may prove to be a more significant development for the specialty biopharmaceutical company, and for the rest of the HAE market.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts